Daiichi Sankyo Company, Limited

Sankyo Company, Limited

Sapporo Medical University

Toshinori Agatsuma

Jun Hasegawa

Toshiaki Ohtsuka

Shu Takahashi

Atsushi Urano

Takehiro Hirai

Keisuke Fukuchi

Daisuke Okajima

Hirofumi Hamada

Tatsuji Matsuoka

Reimi Kawaida

Miki Yamaguchi

Takako Kimura

Takeshi Takizawa

Yumi Matsui

Chigusa Yoshimura

Yasuki Kamai

Sandra Miller

Ulrike Schubert

Kaori Nakahara

Junko Yamaguchi

Kimihasa Ichikawa

Tohru Takahashi

Eisuke Tsuda

Kimihisa Ichikawa

Yoshiharu Hiruma

Ichiro Watanabe

Ingrid Schuster

Dirk Ponsel

Philip Rodley

Robert Mühlbacher

Kathrin-Ladetzki Baehs

Steffen Runz

It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L-L-L-NH&#x2014;(CH)n-L-(CH)n-C(&#x2550;O)&#x2014; wherein the anti-TROP2 antibody is connected to the terminal of L, and the antitumor compound is connected to the carbonyl group of the &#x2014;(CH)n-C(&#x2550;O)&#x2014; moiety with the nitrogen atom of the amino group at position 1 as a connecting position.

Anti-TROP2 antibody-drug conjugate

The present invention provides an antibody which binds to a fibroblast growth factor receptor.

Anti-FGFR2 antibodies and methods of use thereof for treating cancer

Anti-FGFR2 antibodies and pharmaceutical compositions thereof

The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Anti-MST1R antibodies and uses thereof

The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

Anti-EPHA2 antibody

An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.

Antibody targeting osteoclast-related protein Siglec-15

Problem to Be Solved It is intended to provide an antibody having an inhibitory activity against cell malignant transformation and/or tumor cell growth, etc. Solution The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.

The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer based on the expression of the human oculospanin gene as a marker and a pharmaceutical composition containing an antibody capable of specifically recognizing human oculospanin and having cytotoxic activity against cancer cells.

Antibody against tumor specific antigen as target

Growing community of inventors

Tokyo, Japan

Toshinori Agatsuma